- Report
- February 2024
- 150 Pages
Global
From €4123EUR$4,750USD£3,575GBP
- Report
- June 2024
- 170 Pages
Global
From €4336EUR$4,995USD£3,759GBP
- Report
- November 2024
- 203 Pages
Global
From €3863EUR$4,450USD£3,349GBP
- Report
- September 2022
- 173 Pages
North America
From €2995EUR$3,450USD£2,596GBP
- Report
- April 2021
Global
From €3863EUR$4,450USD£3,349GBP
- Report
- December 2024
- 94 Pages
China
From €1562EUR$1,800USD£1,355GBP
- Report
- December 2024
- 267 Pages
China
From €3472EUR$4,000USD£3,010GBP
- Report
- December 2024
- 123 Pages
China
From €1562EUR$1,800USD£1,355GBP
- Report
- August 2024
- 229 Pages
China
From €3472EUR$4,000USD£3,010GBP
From €112EUR$129USD£97GBP
- Report
- August 2024
- 93 Pages
China
From €1562EUR$1,800USD£1,355GBP
- Report
- March 2024
- 132 Pages
Global
From €825EUR$950USD£715GBP
The Macrolide Antibiotic market is a segment of the Infectious Diseases Drugs market. Macrolides are a class of antibiotics used to treat a wide range of bacterial infections, including respiratory tract infections, skin infections, and sexually transmitted diseases. Macrolides are generally well-tolerated and have fewer side effects than other antibiotics. They are also effective against drug-resistant bacteria, making them an important tool in the fight against antibiotic resistance. Macrolides are available in both oral and intravenous formulations, and are often used in combination with other antibiotics.
The Macrolide Antibiotic market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, and Novartis. Show Less Read more
